RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

Summary

The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.

Timeline

Start

2026-01-01

Primary completion

2028-01-01

Completion

2030-01-01

Drugs

Indications